New AI tool to spot skin cancer to be used in NHS
Adults with suspected skin cancer may be initially assessed with a new AI tool after it was approved for NHS use.
The National Institute for Health and Care Excellence (Nice) said that the technology, which has been conditionally approved for the next three years, has the potential to reduce waiting times.
It comes as health experts issued a warning over sun cream ahead of the Bank Holiday weekend.
Melanoma Focus said a large proportion of Britons are frequently letting themselves burn, putting themselves at a higher risk of deadly skin cancer.
AI is being deployed to speed up the diagnosis of skin cancer and free up capacity within dermatology.
DERM assesses and classifies scans of moles or skin lesions that have been taken by a healthcare professional, after patient is referred by a GP for suspected skin cancer. pic.twitter.com/unqGj0Myv7
— Bolton NHS Foundation Trust (@boltonnhsft) April 2, 2025
The new artificial intelligence (AI) tool, DERM (Deep Ensemble for Recognition of Malignancy), works by analysing images of moles or skin lesions to see whether they are potentially cancerous.
The tool, developed by Skin Analytics, can be used by healthcare workers who use a smartphone with a high quality magnifying lens attached, also known as a dermoscopic lens, to take images of suspicious moles, or skin lesions.
The images are then uploaded on to DERM's online platform, which uses AI to analyse the images.
For patients whose moles or lesions are identified as potentially cancerous, a specialist skin doctor, known as dermatologist, will review the case and come up with a plan for the patient.
People whose moles or lesions are not suspicious are either offered reassurance and advice or can be put on a 'non-urgent pathway'.
Nice said that early evidence suggests the automated use of the tool could 'approximately halve the number of referrals to dermatologists within the urgent skin cancer pathway'.
It has been 'conditionally approved' for the next three years, while further evidence is collected, Nice said.
'DERM has shown promising results in its ability to accurately distinguish between cancerous and non-cancerous skin lesions, with evidence suggesting it could halve the number of referrals to dermatologists within the urgent skin cancer pathway while maintaining patient safety,' said Dr Anastasia Chalkidou, healthtech programme director at Nice.
'Our evaluation shows this technology maintains diagnostic accuracy while reducing the burden on specialist dermatology services. By implementing this system within existing pathways, we can ensure patients get the right care more quickly.'
Ashley Dalton, minister for public health and prevention, said: 'By embracing the power of AI, this exciting technology could help us slash waiting times — meaning that people with suspected skin cancer get the help they need, or peace of mind, faster.'
Neil Daly, chief executive of Skin Analytics said: ''We're incredibly proud of the work we've been doing with the NHS over the last five years to achieve this recommendation from Nice. Having seen more than 165,000 patients and found more than more than 15,500 cancers since launching, we are ready to make our Class III autonomous skin cancer AI available to more UK patients.'
The British Association of Dermatologists said in a statement: 'Until further evidence is generated, the British Association of Dermatologists recommends that all patients should have some input from a dermatologist.
'Implementation of AI must be underpinned by patient safety, with a clear understanding of the benefits and limitations.'
The Association said that AI has 'the potential to transform dermatology services' but said that more real-world evidence is needed.
It comes as Melanoma Focus warned about the dangers of sunburn among Britons.
'It is essential that everyone understands the risks associated with sunburn and prioritises sun protection by using factor 30+ sunscreen, wearing a hat, seeking shade and covering up in the heat of the day,' said Susanna Daniels, chief executive of Melanoma Focus.
A poll by Melanoma Focus of 2,000 people aged 16 and over in the UK that almost half (49%) said they are sunburned at least once a year, with higher numbers reported in younger age groups.
Ms Daniels added: 'This data is extremely concerning as we know that more than five sunburns in your lifetime doubles your risk of melanoma, so burning every year has potentially long-term dangerous consequences.
'Nearly nine in 10 melanomas are preventable, yet the UK has more deaths from melanoma per year than Australia.'
The poll also found that 19% said they 'rarely' wear sun cream in the UK between May and September, 8% said they 'never' use sun cream in the UK during this period. Almost one in 10 (9%) said they never wear sun cream at all.
Reasons for avoiding sun cream in the UK included people not expecting to burn; forgetting to apply sun cream and 8% said sun cream is 'too expensive'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Signing up for clinical trials to be new feature on NHS App
Browsing and signing up to clinical trials will become a new feature on the NHS App as part of the Government's healthcare plan. Eventually the app will automatically match patients with studies based on their own interests and health data – and send push notifications with relevant new trials, the Department for Health and Social Care (DHSC) said. The NIHR's (National Institute for Health and Care Research) Be Part of Research service on the app is part of the Government's 10-year health plan. It takes around 100 days to set up a trial in Spain, but approximately 250 days in the NHS, DHSC said. The department projected the plan will see commercial trial set-up times fall to 150 by March 2026, which it described as 'the most ambitious reduction in trial set-up times in British history'. Health Secretary Wes Streeting said: 'The 10-year plan for health will marry the genius of our country's leading scientific minds, with the care and compassion of our health service, to put NHS patients at the front of the queue for new cutting-edge treatments. 'The NHS App will become the digital front door to the NHS, and enable all of us as citizens to play our part in developing the medicines of the future.' He added: 'The British people showed they were willing to be part of finding the vaccine for Covid, so why not do it again to cure cancer and dementia? 'By slashing through red tape and making it easier for patients to take part, reforms in our 10-year plan will grow our life sciences sector, generate news funds for the NHS to reinvest in frontline care, and benefit patients through better medicines.' The number of trials sponsored by commercial and non-commercial entities at specific NHS trusts, as well as organisations including universities, will be made public. This will reveal which are 'performing well and which are falling behind', DHSC added. Funding for NHS trusts will be prioritised for those who perform the best, DHSC said. The app announcement comes as the NIHR launches a UK-wide clinical trials recruitment drive. Studies are 'too slow' to set up in the UK because of 'unnecessary bureaucracy and duplication of activities across different agencies and sites', DHSC said. Researchers must currently agree separate contracts with each relevant area of the NHS, but the Government has pledged to introduce a 'national standardised contract'. Professor Lucy Chappell, chief scientific adviser at DHSC and chief executive of the NIHR, said: 'Ensuring all sites are consistently meeting the 150-day or less set-up time will bring us to the starting line, but together we aim to go further, faster to ensure the UK is a global destination for clinical research to improve the health and wealth of the nation.' The global clinical trials market is estimated to be worth at least 80 billion dollars (around £59 billion) by 2030, said Professor Andrew Morris, president of the Academy of Medical Sciences, which is a fellowship of leading scientists. Those who are under-represented – including young, black and South Asian people – are particularly encouraged to register for trials, DHSC said. Professor Morris added that the app will 'accelerate the translation of cutting-edge treatments from laboratory to bedside' and that making research accessible to all communities can help 'ensure that medical innovation benefits reach every corner of society.' 'The focus on improving participation from under-represented communities is important, though success will depend on earning trust and addressing the broader barriers to diverse participation', he said. Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, welcomed the initiative and said it could 'really increase the number and diversity of people taking part in critically-important dementia research'. 'With a growing pipeline of drugs for Alzheimer's disease currently in trials, it's vital programmes like this streamline recruitment so we can ensure these emerging treatments work for everyone,' he added.
Yahoo
7 hours ago
- Yahoo
NHS faces paying more for US drugs to avoid future Trump tariffs
Britain faces paying more for US drugs as part of a deal to avoid future tariffs from Donald Trump. The NHS will review drug pricing to take into account the 'concerns of the president', according to documents released after a trade agreement was signed earlier this year. White House sources said it expected the NHS to pay higher prices for American drugs in an attempt to boost the interests of corporate America. A Westminster source said: 'There's an understanding that we would look at the drug pricing issue in the concerns of the president.' The disclosure is likely to increase concerns about American interference in the British health service, which has long been regarded as a flashpoint in trade talks. It comes after Rachel Reeves announced a record £29 billion investment in the NHS in last week's spending review. The Chancellor's plans will drive spending on the health service up towards 50 per cent of all taxpayer expenditure by the mid-2030s, according to economists at the Resolution Foundation. The Telegraph has also learnt that under the terms of the trade deal with America, the UK has agreed to take fewer Chinese drugs, in a clause similar to the 'veto' given to Mr Trump over Chinese investment in Britain. The White House has asked the UK for assurances that steel and pharmaceutical products exported to the US do not originate in China, amid fears the deal could be used to 'circumvent' Mr Trump's punishing tariffs on Beijing. Mr Trump is enraged by how much more America pays for drugs compared with other countries and considers it to be the same issue as he has raised on defence spending. Just as the US president has heaped pressure on European nations to increase the GDP share they allocate to defence, he thinks they should spend more on drug development. An industry source said: 'The way we've been thinking about it and many in the administration have been thinking about it, it's more like the model in Nato, where countries contribute some share of their GDP.' Britain and the US 'intend to promptly negotiate significantly preferential treatment outcomes on pharmaceuticals and pharmaceutical ingredients', the trade deal reads. Pharmaceutical companies are also pushing for reductions in the revenue sales rebates they pay to the NHS under the voluntary scheme for branded medicines pricing, access and growth (VPAG) – a mechanism that the UK uses to make sure the NHS does not overpay. Last week, Albert Bourla, Pfizer's chief executive, said non-US countries were 'free-riding' and called for a US government-led push to make other nations increase their proportionate spend on innovative medicines. He said White House officials were discussing drug prices in trade negotiations with other countries. 'We represent in UK 0.3pc of their GDP per capita. That's how much they spend on medicine. So yes, they can increase prices,' Mr Bourla said. Industry sources said there was no indication yet on what the White House would consider to be a fair level of spending. Whatever the benchmark, Britain will face one of the biggest step-ups. UK expenditure on new innovative medicines is just 0.28pc of its GDP, roughly a third of America's proportionate spending of 0.78pc of its GDP. Even among other G7 nations, the UK is an anomaly. Germany spends 0.4pc of its GDP while Italy spends 0.5pc. Most large pharmaceutical companies generate between half and three quarters of their profits in the US, despite the fact that America typically makes up less than a fifth of their sales. This is because drug prices outside of the US can cost as little as 30pc of what Americans pay. Yet, pharmaceutical companies rely on higher US prices to fund drug research and development, which the rest of the world benefits from. A month ago, Mr Trump signed an executive order titled 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients', which hit out at 'global freeloading' on drug pricing. It stated that 'Americans should not be forced to subsidise low-cost prescription drugs and biologics in other developed countries, and face overcharges for the same products in the United States' and ordered his commerce secretary to 'consider all necessary action regarding the export of pharmaceutical drugs or precursor material that may be fuelling the global price discrimination'. Trung Huynh, the head of pharma analysis at UBS, said: 'The crux of this issue is Trump thinks that the US is subsidising the rest of the world with drug prices. 'The president has said he wants to equalise pricing between the US and ex-US. And the way he wants to do it is not necessarily to bring down US prices all the way to where ex-US prices are, but he wants to use trade and tariffs as a pressure point to get countries to increase their prices. 'If he can offset some of the price by increasing prices higher ex-US, then the prices in America don't have to go down so much.' Mr Huynh added: 'It's going to be very hard for him to do. Because [in the UK deal] it hinges on the NHS, which we know has got zero money.' Under VPAG, pharmaceutical companies hand back at least 23pc of their revenue from sales of branded medicines back to the NHS, worth £3bn in the past financial year. The industry is pushing for this clawback to be cut to 10pc, which would mean the NHS would have to spend around 1.54bn more on the same medicines on an annual basis. The Government has already committed to reviewing the scheme, a decision which is understood to pre-date US trade negotiations. A government spokesman said: 'This Government is clear that we will only ever sign trade agreements that align with the UK's national interests and to suggest otherwise would be misleading. 'The UK has well-established and effective mechanisms for managing the costs of medicines and has clear processes in place to mitigate risks to supply.'
Yahoo
10 hours ago
- Yahoo
Completion of £16m medical centre 'firmly in sight'
The completion of a £16m integrated care centre is "firmly in sight" following the installation of a new roof. The Trowbridge Integrated Care Centre in Wiltshire has been described as a "state-of-the-art health and care facility" and is due to open to patients early next year. The site will become the location for the minor injury unit and X-ray department that are currently based within the nearby Trowbridge Community Hospital. Interim executive lead for cancer, planned care and community, Caroline Holmes, said: "The building work is well under way, the finish line is firmly in sight, and local people can now see their new integrated care centre really begin to take shape. Using the latest green technology, such as solar panels and heat pumps, the centre is designed to be fully self-sufficient and net zero carbon. Representatives from Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board (ICB) marked the "milestone" occasion on the recently installed roof. They were joined by the Mayor of Trowbridge, along with a number of NHS colleagues who will soon call the new centre home. Ms Holmes thanked those who had helped bring the new centre to life. She added: "When the very first spades went in the ground, it was difficult to picture how a brand new health and care facility could emerge from what was essentially a very muddy field. Yet, here we are." The new centre is set to be a "flagship location" for local health and care, with teams from many different organisations, including HCRG Care Group, Avon and Wiltshire Mental Health Partnership and the Royal United Hospital, working together under one roof. Follow BBC Wiltshire on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630. New £16m health centre given go ahead Bath and North East Somerset, Swindon and Wiltshire ICB
